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Summary Ovarian tumours were cultured by clonogenic assay and drug sensitivity profiles obtained for cis-
platinum, adriamycin and phosphoramide mustard. Results were correlated with clinical outcome. Two
hundred samples were received from 106 patients and 115/167 with malignant cytology (69%) were cultured
successfully. Drug results were obtained on 71 samples and in untreated patients 60% of samples (48% of
patients) were markedly sensitive to cis-platinum and 87% of samples (76% of patients) were sensitive to
adriamycin. Eighty-one percent of cases sensitive to adriamycin were also sensitive to cis-platinum. Two of 7
samples were sensitive to phosphoramide mustard; the remainder were resistant. Eighty percent of samples
from treated patients were resistant in vitro to drugs already received. Seventy-one samples from 57 patients
were suitable for drug study. Forty-eight patients received chemotherapy, but only 23 received the drugs
tested. Clinical correlations showed that in vitro sensitivity to cis-platinum and adriamycin was related to a
good clinical response. No correlations were observed between cis-platinum and adriamycin resistance in vitro
and clinical ouucome. Unexpected relationships, however, were observed between cis-platinum resistance and
failure to respond to other alkylating agents received singly. No such relationship has been demonstrated for
adriamycin.
Cancer of the ovary is a major clinical problem and
the most common cause of death from
gynaecological malignancy in the United Kingdom.
A particular feature is late presentation and the
majority of patients present with advanced disease.
Selection of effective first-line chemotherapy is
therefore central to effective management.
The development of in vitro assays for the growth
of clonogenic tumour cells in soft agar (Hamburger
& Salmon, 1977; Hamburger et al., 1978) suggested
a system which might be of benefit, not only in
selecting chemotherapeutic regimes following
surgical ablation of tumour, but also in identifying
those drugs to which a patient might be sensitive
after extensive pretreatment. Success in using such a
system has been claimed by Alberts et al. (1980a)
who predicted clinical response based on in vitro
tests in 62% of patients with ovarian cancer and
had an accuracy of 99% in the prediction of
resistance.
Following a pilot study with a small number of
ovarian tumours (Simmonds et al., 1981) this
investigation was undertaken with the aims of (i)
culturing ovarian tumour material using the stem
cell or clonogenic assay, (ii) evaluation of drug
sensitivity to agents in current clinical use and (iii)
correlation of these results with clinical outcome.
It was decided that the methods outlined by
Hamburger & Salmon (1977) would be adhered to
in order to accumulate sufficient data on a large
group of patients. Valid assessment of this system
could then be made.
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Materials and methods
Tumour material
Material from 106 patients was used and was
collected from all hospitals in the Glasgow area.
This constituted 200 samples and included solid
ovarian tumours, omental and uterine deposits,
ascitic fluids, peritoneal washings and pleural
effusions. Samples were taken at both primary and
"second-look" laparotomies and from abdominal
and pleural taps.
Collection ofcells
Solid material was transported in Hanks balanced
salt solution (HBSS) with penicillin and
streptomycin and effusions and washings collected
in flasks with 10 units heparin ml-l. Effusions and
peritoneal washings were centrifuged at 400g for
10min. Cell suspensions obtained were washed
twice by centrifugation in HBSS with 10% heat
inactivated foetal bovine serum (FBS) then
resuspended in Hams F12 with 10% FBS. Solid
tumour material obtained at surgery was
mechanically dissociated under aseptic conditions in
a laminar flow hood. Tumours were minced with
crossed scalpels and then teased apart with needles.
Large clumps were removed by passage through
polyester mesh and the cell suspensions so obtained
were passed through needles of decreasing size to
23 gauge and then washed twice by centrifugation
as described. Careful agitation by repeated pipetting
up and down following resuspension of cells
resulted in single cell suspensions.
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Viable nucleated cell counts were determined by
trypan blue exclusion in a haemocytometer and
reference slides made of each cell suspension.
Staining was with Wright-Giemsa and oil red 0.
Culture assay
Cells were cultured as described by Hamburger &
Salmon (1977). One ml underlayers containing
0.5ml of Millipore filtered medium conditioned by
the adherent spleen cells of mineral oil primed
Balb/c mice in 0.5% agar were prepared in 30mm
Petri dishes. Cells to be tested were suspended in
0.3% agar in enriched CMRL 1066 medium with
15% horse serum. Each plate received 2 x 105 viable
cellsml-I of agar: medium mixture and each assay
was set up in quadruplicate. Cultures were
examined under the microscope immediately after
plating and those plates bearing identifiable clumps
were discarded. To test for the relationship between
the number of cells inoculated and the number of
colonies formed, additional cultures were set up
over a range of inoculum concentrations. Cultures
were incubated at 37°C in a 5% C02/95% air
humidified atmosphere for 10 days.
Scoring ofcultures
Cultures were examined with an inverted phase
microscope at x 100 and x 200. Aggregates of > 32
cells were considered colonies and replicate plates
were stained with Coomassie blue (Salmon & Liu,
1979) to facilitate counting. The plating efficiency
(PE) of each sample was calculated from mean
values of colony counts for 4 plates. Representative
colonies were plucked at random from the dishes
with a fine Pasteur pipette and deposited on slides
with a drop of heat inactivated FBS. After air
drying, slides were stained in the same manner as
those for original cell preparations.
Drug sensitivity testing
Drugs used were cis-platinum diammine dihydro-
chloride (Neoplatin, Mead Johnson), adriamycin
(Farmitalia Carlo Erba Ltd.) and cyclophosphamide
- phosphoramide mustard derivative (NCI NSC-
69945 - kindly supplied by the Drug Synthesis and
Chemistry Branch, Division of Cancer Treatment,
NCI, NIH. Bethesda, Maryland, USA). These were
the constituents of the CAP regime in current use
for management of ovarian cancer. Doses received
clinically were cyclophosphamide 600mg m 2,
adriamycin 40mg m-2 and cis-platinum 50mg m-2
given i.v. at 3-4 week intervals to a total of 6
pulses.
Values for in vitro drug concentrations used were
those of Alberts et al. (1980b) for cis-platinum and
adriamycin and a range of concentrations up to the
peak plasma concentration for phosphoramide
mustard.
Single cell suspensions prepared as described
were adjusted to a final concentration of 2x 106
viable cellsml-1 in Hams F12 medium with 10%
FBS. Aliquots of 0.5ml cell suspension were then
mixed thoroughly with 0.5ml of double strength the
appropriate drug concentration in Hams F12
medium and incubated at 37°C without shaking for
one hour. Drug was removed by centrifugation at
400g for 10min and the cell pellet washed twice by
centrifugation in HBSS with 10% heat inactivated
FBS. Control cultures were treated similarly, but
incubated in medium alone. All cells were then
suspended in CMRL 1066 agar medium and plated
as described.
At 10 days incubation, colony numbers were
counted and compared to those on the control
plates. Results were expressed as mean percentage
survival of colonies at each drug concentration and
represented on a linear dose response curve.
Assessment of response to cis-platinum and
adriamycin was made using the "sensitivity indices"
for area under the curve described by Alberts et al.
(1980a, b) and based on a <50% survival at 10%
the peak plasma concentration on a log linear dose
response curve for phosphoramide mustard. Only
samples with a minimum of 30 colonies in control
plates were evaluated for drug sensitivity.
Clinical data
Information about clinical response was obtained
through the West of Scotland Clinical Trials Unit
at Glasgow University Department of Clinical
Oncology, courtesy of Prof K.C. Calman. Forms
designed for the purpose were sent out at 6-month
intervals to the consultants involved, requesting
details of disease status, response to the
chemotherapeutic regime of choice and plans for
future management. Responses were measured by
palpation, CAT scan and "second-look"
laparotomy. A complete response (CR) was
denoted by complete disappearance of all clinically
detectable malignancy for at least 4 weeks and a
partial response (PR) was classified as an objective
decrease in measurable tumour mass by 50%. All
such information received was correlated with the
drug results obtained.
Results
Culture
Successful culture as measured by colony formation
of at least 10 colonies per dish at 10 days was
observed for all the histological tumour types
received and in every type of sample. Table IOVARIAN TUMOUR DRUG RESPONSE BY STEM CELL ASSAY
Table I Successful culture of ovarian carcinoma material in relation to sample
numbers with malignant cytology.
No. ofsamples Percentage
No. with malignant Successful successful
Sample type ofsamples cytology culture culture
Solid ovarian tumour 93 89 64/89 72
Ascitic fluids 66 54 37/54 69
Omental deposits 10 8 7/8 88
Uterine deposits 4 4 3/4 75
Peritoneal washings 23 10 2/10 20
Pleural effusions 4 2 2/2 100
illustrates the percentage of such cultures related to
sample type and expressed in relation to the number
of samples with positive cytology. Of a total
sample number of 167 with malignant cytology, 115
were cultured successfully, a percentage success rate
of 69%. Most ovarian solid tumours grew, as did
deposits from the uterus and omentum. Culture of
peritoneal washings was least successful, in spite of
positive cell viability tests. Likewise some ascitic
samples failed to grow and it is possible that many
of such samples do not have the capacity for
further growth, since the failures were
predominantly in cultures from patients with Stage
III widespread intraperitoneal metastasis impossible
to debulk surgically or from abdominal taps on
those with advanced disease. Only 2/4 pleural
effusions contained malignant cells, but these grew
well in culture.
Plating efficiencies observed were in the range
0.009% to 0.6% in control plates, although the
majority of samples (60%) had PEs of between
0.01% and 0.1%. This still excluded many samples
from assessment for significant drug results. To
assess the precision of the scoring technique, the
values for 48 samples were analysed and the
coefficient of variation calculated for each set of
replicate determinations, including drug treated
plates. In the range of colonies counted 6-1025, the
mean coefficient ofvariation was 12.4%.
To exclude the possible influence of extreme
values, the mean coefficient of variation was
recalculated in the range 10-100 colonies and found
to be 11.4%. This represented 39 of the 48 samples.
Linearity ofcolonyformation
For 6 samples studied, a linear relationship was
observed between the number of nucleated cells
plated and the number of colonies formed. This
held good over the range studied, from 5 x 104 to
106 cells per dish. No relationship was observed
between colony size and colony numbers. Further
investigations were precluded by paucity of cells
remaining after drug study.
No relationship was observed between tumour
type and either plating efficiency or successful
culture. Eighty per cent of the papillary
cystadenocarcinomas grew; these constituted 45%
of all samples obtained. Eighty-one percent of
poorly differentiated adenocarcinomas, 75% of
endometrioid carcinomas and only 50% of the
mucinous cystadenocarcinomas were cultured
successfully. Mixed mesodermal and clear celled or
mesonephroma tumours, constituting 4 samples,
grew, but a Kriikenberg deposit and a teratoma did
not.
Viability of initial cell suspensions was higher
than expected. Greater than 60% of tumour
samples received had cell viabilities of > 80%.
Colony cellmorphology
Colony cells stained with Wright-Giemsa were
compared morphologically with cell preparations
from the original suspension. Initially this
comparison was made for every sample, but later
comparisons were made on every tenth sample under test.
Cells from papillary cystadenocarcinoma were
ovoid with pale staining cytoplasm and irregular nuclei with one or more nucleoli. Those from
mucinous cystadenocarcinoma were larger with
small nuclei and large vacuoles. Poorly differentiated adenocarcinoma cells were frequently multinucleated and consistently vacuolate.
Oil red 0 positive granules were found in both
papillary and poorly differentiated adenocarcinoma
cells. Those derived from colonies, however, had
only a weakly positive reaction.
Colony morphology was similar for all
histological types. Cells were tightly packed and
markedly vacuolated.
Drug sensitivity testing
The low plating efficiencies observed in culture
rendered many samples unsuitable for drug testing and several further samples yielded insufficient
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material to proceed. Of the 115 samples which grew
in culture, only 88 (77%) yielded sufficient cells to
study one or more drugs. Of these, only 71,
representing 62% of the original samples cultured
successfully, had plating efficiencies high enough
for significant drug results.
All 71 samples were tested against cis-platinum
and results were also obtained for adriamycin on 35
samples and for phosphoramide mustard on 9
samples.
By measuring area under the curve in units on a
linear dose: response plot, samples were classified
as sensitive, intermediate or resistant to cis-
platinum and as either sensitive or resistant to
adriamycin. For phosphoramide mustard,
percentage survival at 10% the peak plasma
concentration (3.5 ugml-1) was calculated and
samples classified as sensitive if fewer than 50% of
the colonies survived at this concentration.
Response to cis-platinum Patterns of response of
ovarian tumour samples to cis-platinum are shown
in Figure 1. The response of material from
untreated patients is shown in Figure la and b and
that from pre-treated patients in Figure Ic and d.
Of the 66 samples with no previous drug exposure,
39 (- 60%) showed sensitivity, 16 were
intermediate and 11 were resistant. However,
according to the classification of Salmon et al.
(1980), for in vitro/in vivo correlation the
intermediate samples are classed as sensitive.
Untreated
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Therefore 55/66 samples (83%) would be classified
as having a response to this drug in vitro. This
represented 41 patients (79% of total). Only 25
patients (48%), however, were truly sensitive.
Of the 5 samples exposed to cis-platinum
previously (Figure lc and d) one retained sensitivity
while the others were markedly resistant.
Response to adriamycin The results with
adriamycin (Figure 2) were similar to those
observed for cis-platinum. Of the 30 samples not
previously exposed to this drug (Figure 2a and b),
26 (87%) representing 76% of patients were
markedly sensitive and 4 were resistant.
Of the 5 samples previously exposed to
adriamycin (Figure 2c and d) only one was sensitive
while the remainder were resistant.
Response to phosphoramide mustard The response
of the 9 samples tested is shown in Figure 3. None
had previously been exposed to cyclophosphamide.
Two samples were sensitive and the remainder were
resistant.
Relationship between drug sensitivities
Untreated material In samples from patients who
had not received any cytotoxic therapy, those
sensitive to adriamycin were also sensitive to cis-
platinum with 5 exceptions. In 4 of these instances,
the samples were judged to have an intermediate
Pretreated
c
2 0 0.1 02
d
0
0
01 02
,ug ml- adriamycin
Figure 1 In vitro response of ovarian tumour material to cis-platinum; (a) and (b) from untreated patients
and (c) and (d) from pre-treated patients. Sensitivity is demonstrated in (a) and (c) and resistance in (b) and
(d).
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Figure 2 In vitro response of ovarian tumour material to adriamycin; (a) and (b) from untreated patients and
(c) and (d) from pre-treated patients. Sensitivity is demonstrated in (a) and (c) and resistance in (b) and (d).
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Figure 3 In vitro response of ovarian
to phosphoramide mustard. All
resistance to adriamycin and sensitivity to cis-
platinum observed in the same patient.
The two samples sensitive to phosphoramide
mustara were sensitive to botn cis-piatinum ana
adriamycin. However, those samples resistant to
phosphoramide mustard were also sensitive to cis-
platinum and adriamycin with the exception of one.
This sample was resistant to all 3 drugs. No
relationship was observed in this small group of
samples which would indicate that sensitivity in
vitro to one alkylating agent was related to
response to another.
Pretreated material For both cis-platinum and
adriamycin, the 5 pretreated samples are
1.0 10 35 representative of 5 patients. Four of these were
stard resistant to both drugs and one remained sensitive Stard after exposure. Since all patients had been exposed
umour material to both drugs, no conclusions can be drawn about
patients were the development of cross resistance.
untreated and (a) demonstrates sensitivity and (b)
demonstrates resistance.
response to cis-platinum. Therefore, 81 % of
samples with response to adriamycin were also
sensitive to cis-platinum. This was true for both
ascitic fluid and solid ovarian tumour.
Where resistance to adriamycin was observed,
cis-platinum response was either overtly resistant or
was judged to be intermediate. In no instance were
Clinical correlations
Clinical follow-up revealed that some patients died
without treatment and others had radiotherapy
alone, while half of those who received
chemotherapy were either considered unsuitable for
placement in a clinical trial or the drugs were
abandoned due to toxicity. Thus, of the 57 patients
represented by the 71 samples available for drug
study, only 48 received chemotherapy, of whom 23
received the drugs of test.
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Table II Relationship between in vitro chemosensitivity and clinical outcome in
patients receiving drugs of test.
Response Response
Sample to to
no. cis-platinum adriamycin Chemotherapy Outcome Correlation
84 S CAPx7 PR Y
105 S CAPx7 PR Y
106 S CAPx2 PR Y
113 S CAPx6 PR Y
138 S S cyclo/plat PR Y/-
165 S S CAP x4 PR Y
172 S S CAP x 7 PR Y
176 S S CAPx6 CR Y
186 S S CAPx6 CR Y
199 S S cyclo/adr CR -/Y
225 S CAP x 6 CR Y
135 Int CAPx5 0 ?
181 Int S cyclo-plat P N
185 Int S CAP x 6 PR Y
190 Int S CAP x1 P N
192 Int S CAP x 6 PR Y
215 Int R CAP x 4 P ?
115 R CAPx6 CR N
144 R S cyclo/adr PR -/Y
213 R CAPx6 CR N
218 R R CAP x4 0 ?
237 R R CAPx4 0 ?
241 R R CAP x 3 0 ?
R=resistant; S=sensitive; Int=intermediate;
adriamycin and cis-platinum; PR=partial response;
P=progression; 0 =stable; Y=yes; N=no; ?=equivocal.
Table II illustrates the outcome in those patients sensitive to
who received either cis-platinum or adriamycin as CAP regimi
part of their chemotherapy. Eleven patients were patients ha(
judged sensitive to cis-platinum and 10 received it regime but I
in some form. Seven achieved good partial all had Sta
responses and 3 obtained complete responses on the intermediate
therapy as shown. Adriamycin sensitivity was purpose of (
known for 6 of these patients, of whom 5 received patients 18
it and had a good response. For this group of relationship.
patients, therefore, in vitro sensitivity to cis- Of the 6
platinum and adriamycin was related to a good platinum, 5
clinical response to these drugs when received in resistant to
therapy. Two of the patients who had complete on their C
response to the CAP regime were known to be objective ir
sensitive to phosphoramide mustard in vitro, but no patients had
results were available for the remaining samples. Correlation
One further patient, judged resistant to for 2 patier
phosphoramide mustard and sensitive to cis- others.
platinum and adriamycin, received If the re
cyclophosphamide as a single agent and failed to adriamycin i
respond, but later had a good response to the CAP vivo correla
regime. relationship.
Of the 6 patients judged to have an intermediate vitro, no corn
response to cis-platinum, 4 were known to be Overall, ci
CAP=cyclophosphamide,
CR=complete response;
adriamycin of whom 3 received the
le. Results here are equivocal, as 2
d good partial responses to the full
progressed after only 1 pulse, although
ge III disease at laparotomy. If an
response is classed as sensitive for the
correlation (Salmon et al., 1980), then
,9 and 192 also demonstrate some
patients judged to be resistant to cis-
received this drug. Three were also
adriamycin and are stable at this time
"AP chemotherapy having shown no
mprovement clinically. Two further
complete responses to the CAP regime.
in this small group of patients is poor
nts and cannot yet be made for the
sults are assessed on the basis of
response, there is a strong in vitro/in
lion. Eight of 9 cases showed this
Where adriamycin resistance occurs in
relation can yet be made.
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related to good clinical response to a regime which
contains it. Although it is noteworthy that
sensitivity to cis-platinum and adriamycin have
been found consistently together, it remains to be
determined whether response to each element of a
combination when tested singly is necessary for the
combination itself to be clinically effective.
Prediction of chemosensitivity The relationship
between clinical response to other drugs and in
vitro response to cis-platinum and adriamycin in
those patients who received alternative therapy is
shown in Table III.
Of the 20 patients who fell into this category and
have been assessed, 2 had been extensively pre-
treated, were resistant in vitro to cis-platinum which
they had not received and died having failed to
respond to further therapy (patients 177' and 212').
However, patient 84' had been pretreated with cis-
platinum to which she had at first responded but
died having failed to respond to another second line
alkylating agent.
When in vitro resistance to cis-platinumn in
untreated patients is related to clinical outcome
when alternative alkylating agents are received, the
correlation holds good in that all 5 cases progressed.
Four of these received single alkylating agents. If
sensitivity to cis-platinum in vitro is related to
clinical outcome, no correlation is found. Eleven of
12 such patients failed on single alkylating agent
chemotherapy. Adriamycin response in vitro is
similarly unrelated to a generalized
chemosensitivity. Six of 7 patients sensitive to
adriamycin progressed on their chemotherapy.
Discussion
In this study we have shown that ovarian tumour
material can be cultured successfully by clonogenic
assay and that such cultures can be used to obtain
in vitro sensitivity measurements to drugs in current
use.
No relationship has been observed between the
plating efficiencies recorded and either tumour type
or stage of disease. Although samples of similar
pathology exhibited broadly similar characteristics
in culture and are clearly derived from tumour cells
in the original suspensions, the growth rate of each
sample is distinct and only in few instances have
such rates been correlated with suggested rate of
spread of disease.
Successful culture was achieved with all types of
malignant material tested and tumour cell viabilities
after mechanical disaggregation (. 80% for 60% of
samples) were good. With the exception of
peritoneal washings, culture success rates were high
(69%-88%) and the total percentage successful
Table III Relationship between in vitro chemosensitivity and clinical outcome in
patients receiving alternative chemotherapy.
Response Response
Sample to to
no. cis-platinum adriamycin Chemotherapy Outcome Correlation
81 S Chlorambucil P N
84' R Treosulphan P Y
89 S - Treosulphan 0 ?
90 R Cyclo Adr5FU P Y
101 S Cyclophosphamide P N
102 S - Treosulphan P N
103 S Cyclophosphamide P N
104 R Treosulphan P Y
112 R Chlorambucil P Y
119 R - Cyclophosphamide P Y
132 S Chlorambucil P N
146 S S Treosulphan{MTx p N
148 S S Chlorambucil + Y
158 S S Chlorambucil P N
162 S S Treosulphan P N
165 S S Cyclophosphamide P N
177' R R Thiotepa P Y
178 R S Treosulphan P Y/N
189 S S Treosulphan P N
212' R Treosulphan P Y
(')=pretreated; R=resistant; S=sensitive; + =response; P=progression;
0=stable; Y=yes; N=no; ?=equivocal.324 A.P. SIMMONDS & E.C. McDONALD
culture rate of 69% compares favourably with
those reported by other workers (Hamburger et al.,
1978; Ozols et al., 1980a).
We have also demonstrated that 60% of samples
representing 48% of previously untreated patients
were sensitive to cis-platinum and that this number
may be higher if "intermediate" values are
regarded as sensitive. Only 17% of untreated
samples were overtly resistant to cis-platinum.
Similarly, 87% of untreated samples were markedly
sensitive to adriamycin when tested and only 13%
were resistant. These values for adriamycin
compare with those of Ozols et al. (1980b) who
used the same period of drug incubation but
different parameters for sensitivity (70% reduction
in colony forming cells at clinically achievable
plasma levels).
Sensitivity to phosphoramide mustard in culture
was observed in only 22% of samples, but it may
be that the parameters for sensitivity discrimination
were too stringent. Additionally, it has been
suggested (Powers & Sladek, 1983) that
phosphoramide mustard might not be the active
metabolite in patients where cyclophosphamide is
of therapeutic value. As the group of patients was
small and few received this chemotherapy, it has
not been possible to make adjustments based on
clinical outcome.
Although the group of patients pretreated with
cis-platinum and adriamycin was small, it has been
demonstrated that 80% of samples taken from such
patients are overtly resistant to these drugs. These
figures for adriamycin again concur with those of
Ozols et al. (1980b) who observed the same patterns
of response in pretreated patients. Such a clear
demonstration of overt resistance may be an
important factor in the management of those
patients where a partial response to chemotherapy
is not achieved rapidly. One such patient (177')
failed on further alkylating agent chemotherapy.
Some interesting relationships between drug
sensitivities have been observed. Eighty-one per
cent of patients sensitive to adriamycin were also
sensitive to cis-platinum, while those patients
resistant to the drug failed to show a good response
to cis-platinum. Resistance to adriamycin and
sensitivity to cis-platinum were never observed in
the same patient. No relationship exists, however,
between sensitivity to these drugs and a sensitivity
to phosphoramide mustard in vitro.
It is likely, therefore, that patients given a drug
combination which includes cis-platinum and
adriamycin will show a response rate of at least 40-
50%. These figures are derived from the fact that
48% of untreated patients tested are sensitive to
cis-platinum and that many of these are likely to be
sensitive to adriamycin. De Paulo et al. (1975)
quote just such response rates for adriamycin in
advanced ovarian carcinoma. However, this is
much less than is suggested by the in vitro results
with adriamycin and the reasons for this
discrepancy are not apparent. Cohen et al. (1983)
quote response rates for cis-platinum plus
adriamycin at 79-90%, and those for cis-platinum
alone at 40-46%.
We have also shown quite clearly that in vitro
sensitivity to cis-platinum and adriamycin was
correlated with in vivo response, provided that only
truly sensitive cis-platinum results were compared.
Equivocal correlations were obtained when in vitro
sensitivities to cis-platinum were regarded as
intermediate. For the few samples which were
resistant to cis-platinum and adriamycin in vitro, no
clear correlations can yet be made.
A strong relationship exists, however, between
cis-platinum resistance in vitro and failure to
respond to other alkylating agents. This was true
for both pretreated and untreated patients and, in
the case of the untreated patients, was an
unexpected finding. No correlation has been
observed between adriamycin or cis-platinum
response in vitro and sensitivity to other
chemotherapy.
This is in contrast to the observations of the
KSST group (1981) who found that adriamycin
sensitivity was found to correlate with clinical
response, even when the patient was not treated
with this drug.
Any discussion of the relative merits of the
clonogenic assay must include (a) analysis of its
performance as a useful, reproducible laboratory
procedure and (b) its possible clinical usefulness in
the management of cancer patients and how this
may be achieved.
The performance of this assay as a reproducible
test in the laboratory has been established and the
percentage of samples cultured successfully
compares well with workers using other
methodologies (Wilson & Neal, 1981).
Our culture success rates are superior to those of
Williams et al. (1983) but in common with these
and other workers, we have reservations about the
low plating efficiencies associated with this method
(Bertoncello et al., 1982; Rupniak & Hill, 1980). As
a consequence of this, too few samples are
evaluable for drug study. Although 62% of our
samples gave drug results in comparison to Von
Hoff et al. (1981) who found that only 25% of
samples were evaluable, in practice this number was
much lower once changes in therapeutic regimes
had been accounted for. Studies by Courtenay &
Mills (1978) have indicated that it is possible to
improve plating efficiencies and colony size by a
combination of low oxygen and the presence of rat
RBC, although there is not general agreement that
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clear that some modifications along these lines are
necessary to improve performance of this test.
Similarly, small sample size is a problem which
has greater implications for the production of drug
results than is true for assays which depend on the
establishment of monolayers, since the number of
cells derived at the outset determines the number of
tests which may be made (Bertoncello et al., 1982).
Samples from "first" laparotomies are often
generous, but it is at "second-look" laparotomies
or the tapping of effusions from patients who have
progressed, that the provision of samples large
enough for drug testing for possible second-line
chemotherapy is vital. It is at this time either that
samples cannot be obtained or the cell yield is too
low. From a consideration of technical limitations,
therefore, it is clear that, not only must culture
conditions be modified to improve plating efficiency
but that several drugs which the patient has not
received be tested at one concentration alone to
maximise the use ofmaterial.
The potential of the clonogenic assay in the
clinical context could be realised by the adoption of
several strict procedures. All the likely
chemotherapy for a particular patient should be
tested at the outset. Although most centres enter all
suitable patients into clinical trials and few use
single agent chemotherapy, the testing of 4 or 5
drugs should cover all possible treatment.
Therefore, each sample should be split so that these
drugs can be tested at single concentrations
representing 10% of the peak plasma
concentration. Sensitivity would be determined as a
less than 50% survival at these concentrations. The
majority of samples would be sensitive under these
conditions, but a significant number may exhibit
resistance to one or more drugs. If the resistance is
to cis-platinum, it is unlikely that patients would
respond to other alkylating agents.
Samples from patients who have progressed on
their chemotherapy should only be tested against
drugs which they have not received, if sample sizes
are small. Such tests should be able to demonstrate
any residual sensitivity.
In this way, the fullest possible information
about likely response to chemotherapy would be
made available for use in management. Although it
is unlikely that fixed regimes would be changed as a
result of these tests, this assay may have
considerable benefit in the choice of drugs for
patients who have relapsed.
It is clear that the usefulness of this assay in
determining patient management remains to be
tested. The value of such an in vitro system lies in
predicting resistance in those groups of previously
untreated patients who will fail to respond to their
chemotherapy and in predicting sensitivity in
patients who have progressed on their existing
regimes or who for other reasons, such as toxicity
or second-line chemotherapy for residual disease,
require alternative drugs. No useful clinical
information can be gained by testing drugs to
which a patient is already demonstrably clinically
resistant and such demonstrations do nothing to
validate this system.
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